A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• Healthy volunteers accepted
• Adult, Older adult

Study population: Subjects cared for in the ILD (Interstitial Lung Disease)clinic

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Conditions

Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder

Keywords

Interstitial lung diseases, idiopathic pulmonary fibrosis, Sarcoidosis, mRNA and cytokine expression

Medical subject headings

Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Natural history of course of disease in patients with Interstitial lung disease (ILD)

   We assess mortality roughly yearly but duration is unlimited

   Measured: Yearly

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted7 May 2007 (estimated)
2. Study startSep 2005
3. Primary completionDec 2030 (estimated)
4. Study completionDec 2030 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Interstitial Lung DiseasesStudies of the same condition, open and under way.
• More trials run by University of ChicagoThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.